XML 77 R63.htm IDEA: XBRL DOCUMENT v3.4.0.3
Acquisition (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Oct. 25, 2015
Jun. 24, 2015
Feb. 27, 2016
Nov. 28, 2015
Aug. 29, 2015
May. 30, 2015
Feb. 28, 2015
Nov. 29, 2014
Aug. 30, 2014
May. 31, 2014
Feb. 27, 2016
Feb. 28, 2015
Mar. 01, 2014
Apr. 02, 2015
Preliminary purchase price                            
Cash consideration $ 116,500                          
Preliminary purchase price allocation                            
Goodwill     $ 1,713,475       $ 76,124       $ 1,713,475 $ 76,124    
Estimated Useful Life                     10 years      
Reduction in amortization expense     (4,739)                      
Acquisition costs                     $ 27,402 15,442    
Unaudited pro forma combined financial data                            
Bridge loan commitment fees incurred with the Acquisition by both the Company and EnvisionRx                     15,375      
Net revenues     8,270,136 $ 8,154,184 $ 7,664,776 $ 6,647,561 6,847,929 $ 6,692,333 $ 6,522,584 $ 6,465,531 30,736,657 26,528,377 $ 25,526,413  
Less pre-acquisition intercompany revenue                     (103,363) (272,530)    
Pro forma combined revenues                     32,368,929 30,528,863    
Income (loss) before income taxes     101,184 108,011 37,932 31,277 119,067 106,717 147,709 53,327 278,404 426,820 250,218  
Net income     65,617 $ 59,543 21,469 $ 18,836 1,835,032 104,846 $ 127,849 $ 41,446 165,465 2,109,173 249,414  
Incremental interest expense on the 6.125% Notes issued on April 2, 2015                     (11,097) (115,407)    
Incremental amortization resulting from fair value adjustments of the identifiable intangible assets                     (14,297) (48,586)    
Transaction costs incurred by both the Company and EnvisionRx                     56,194 16,199    
Debt extinguishment charges incurred by EnvisionRx         $ (33,205)     $ (18,512)     (33,205) (18,512) $ (62,443)  
Income tax benefit (expense) relating to pro forma adjustments                     (15,866)      
Pro forma net income                     $ 188,677 $ 2,032,294    
Basic income per share                     $ 0.18 $ 2.03    
Diluted income per share                     $ 0.18 $ 1.95    
Pharmacy Services                            
Preliminary purchase price allocation                            
Goodwill   $ 1,637,351 1,637,351               $ 1,637,351      
Amount of goodwill deductible for tax purpose   $ 1,360,156                        
Unaudited pro forma combined financial data                            
Net revenues                     4,103,513      
6.125% senior notes due 2023                            
Acquisitions                            
Principal amount of debt     $ 1,800,000       $ 1,800,000       $ 1,800,000 $ 1,800,000    
Debt instrument, stated interest rate (as a percent)     6.125%       6.125%       6.125% 6.125%    
EnvisionRx                            
Acquisitions                            
Ownership interest (as a percent)   100.00%                        
Stock consideration (in shares)   27,754                        
Share price   $ 8.68                        
Preliminary purchase price                            
Cash consideration   $ 1,882,211                        
Stock consideration   240,907                        
Total   2,123,118                        
Preliminary purchase price allocation                            
Cash and cash equivalents   103,834                        
Accounts receivable   896,473                        
Inventories   7,276                        
Prepaid expenses and other current assets   13,386                        
Total current assets   1,020,969                        
Property and equipment   13,196                        
Intangible assets(1)   646,600                        
Goodwill   1,637,351                        
Other assets   7,219                        
Total assets acquired   3,325,335                        
Accounts payable   491,672                        
Reinsurance funds held   381,225                        
Other current liabilities(2)   216,937                        
Total current liabilities   1,089,834                        
Other long term liabilities(3)   112,383                        
Total liabilities assumed   1,202,217                        
Net assets acquired   2,123,118                        
Estimated Fair Value of Finite lived intangible assets   646,600                        
Change in goodwill resulting from changes to the preliminary purchase price allocation     $ 158,278                      
Reduction in intangibles     $ (178,500)                      
EnvisionRx | Trademarks                            
Preliminary purchase price allocation                            
Estimated Fair Value of Finite lived intangible assets   33,500                        
EnvisionRx | Customer relationships                            
Preliminary purchase price allocation                            
Estimated Fair Value of Finite lived intangible assets   $ 465,000                        
Estimated Useful Life   17 years                        
EnvisionRx | CMS license                            
Preliminary purchase price allocation                            
Estimated Fair Value of Finite lived intangible assets   $ 57,500                        
Estimated Useful Life   25 years                        
EnvisionRx | Claims adjudication and other developed software                            
Preliminary purchase price allocation                            
Estimated Fair Value of Finite lived intangible assets   $ 59,000                        
Estimated Useful Life   7 years                        
EnvisionRx | Trademarks                            
Preliminary purchase price allocation                            
Estimated Fair Value of Finite lived intangible assets   $ 20,100                        
Estimated Useful Life   10 years                        
EnvisionRx | Backlog                            
Preliminary purchase price allocation                            
Estimated Fair Value of Finite lived intangible assets   $ 11,500                        
Estimated Useful Life   3 years                        
EnvisionRx | 6.125% senior notes due 2023                            
Acquisitions                            
Principal amount of debt                           $ 1,800,000
Debt instrument, stated interest rate (as a percent)                           6.125%
EnvisionRx                            
Unaudited pro forma combined financial data                            
Net revenues                     $ 1,735,635 $ 4,273,016    
Net income                     (45,307) 14,031    
Interest expense incurred by EnvisionRx                     21,984 $ 56,884    
Debt extinguishment charges incurred by EnvisionRx                     $ 31,601